Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02537821
Other study ID # PKSF-01-2014
Secondary ID
Status Recruiting
Phase N/A
First received July 1, 2015
Last updated November 20, 2017
Start date June 2015

Study information

Verified date November 2017
Source University of Zurich
Contact Jan Plock, M.D.
Phone 0041 (0)44 2551111
Email jan.plock@usz.ch
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Primary goal of this study is the analysis of HLA (Human leucocyte antigen) formation in severly burned patients. Potential HLA triggers in the treatment of severely burned patients are blood products, assist devices or temporary allogeneic skin. Besides that, inflammatory markers, such as WBC (white blood cell count), CRP (C-reactive protein), PCT (Procalcitonin) and two novel biomarkers (PSP (pancreatic stone protein), ST2) are to be investigated in severely burned patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- severely burned patients in need for hospitalization

Exclusion Criteria:

- hematologic diseases

- Cancer

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Switzerland University Hospital Zurich Zurich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary HLA antibody formation (HLA Sensitization) (Unit: PRA in %) The degree of sensitization is reported as the percentage of CDC (Complement dependent Cytotoxicity) Panel Reactive Antibody (PRA). Unit is %. Change from Baseline (admission) in HLA antibody count at 2 weeks, 4 weeks, 3 months and 6 months